The FDA has approved insulin icodec (Awiqli) from Novo Nordisk. It is the first long-acting basal insulin that is administered only once a week. It is intended for adult patients with type 2 diabetes to control blood sugar levels. Insulin icodec is therefore an alternative to daily administration of basal insulin. A previous application for approval of this product was rejected by the agency.